نتایج جستجو برای: das28

تعداد نتایج: 1719  

2013
Emese Balogh Joao Madruga Dias Carl Orr Ronan Mullan Len Harty Oliver FitzGerald Phil Gallagher Miriam Molloy Eileen O’Flynn Alexia Kelly Patricia Minnock Madeline O’Neill Louise Moore Mairead Murray Ursula Fearon Douglas J Veale

INTRODUCTION Our objectives were to assess the frequency and sustainability of American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) and Disease Activity Score (DAS)28(4v)-C-reactive protein (CRP) remission 12 months after the initiation of tumour necrosis factor inhibitor (TNFi) therapy in a rheumatoid arthritis (RA) cohort. METHODS Data were collected of 273 biol...

2010
Norihiro Nishimoto Nobuhiro Takagi

As tocilizumab (TCZ) greatly inhibits inflammatory markers, methods of evaluating rheumatoid arthritis (RA) disease activity that include inflammatory markers may overestimate the effect of TCZ treatment. We have evaluated the impact of inflammatory markers on the efficacy of TCZ by comparing the efficacy indicated by the 28-joint disease activity score using erythrocyte sedimentation rate (DAS...

2015
Michelle J. Ormseth Cecilia P. Chung Annette M. Oeser Margery A. Connelly Tuulikki Sokka Paolo Raggi Joseph F. Solus James D. Otvos C. Michael Stein

INTRODUCTION GlycA is a novel inflammatory biomarker measured using nuclear magnetic resonance (NMR). Its NMR signal primarily represents glycosylated acute phase proteins. GlycA was associated with inflammation and development of cardiovascular disease in initially healthy women. We hypothesized that GlycA is a biomarker of disease activity and is associated with coronary artery atherosclerosi...

2016
Ru Li Jin-Xia Zhao Yin Su Jing He Li-Na Chen Fei Gu Cheng Zhao Xue-Rong Deng Wei Zhou Yan-Jie Hao Yu Xue Hua-Xiang Liu Yi Zhao Qing-Hua Zou Xiang-Yuan Liu Ping Zhu Ling-Yun Sun Zhuo-Li Zhang He-Jian Zou Xing-Fu Li Yi Liu Yong-Fei Fang Edward Keystone Iain B. McInnes Zhan-Guo Li

OBJECTIVES To determine whether prolonged intensive disease-modifying antirheumatic drug (DMARD) treatment (PRINT) leads to high remission and low relapse rates in patients with severe rheumatoid arthritis (RA). METHODS In this multicenter, randomized and parallel treatment trial, 346 patients with active RA (disease activity score (28 joints) [DAS28] (erythrocyte sedimentation rate [ESR]) > ...

2012
Darren Plant Ibrahim Ibrahim Mark Lunt Stephen Eyre Edward Flynn Kimme L Hyrich Ann W Morgan Anthony G Wilson John D Isaacs Anne Barton

INTRODUCTION In many European countries, restrictions exist around the prescription of anti-tumor necrosis factor (anti-TNF) treatments for rheumatoid arthritis (RA). Eligibility and response to treatment is assessed by using the disease activity score 28 (DAS28) algorithm, which incorporates one of two inflammatory markers, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Alth...

2017
Brian C. Sauer Chia-Chen Teng Neil A. Accortt Zachary Burningham David Collier Mona Trivedi Grant W. Cannon

BACKGROUND This study developed and validated a claims-based statistical model to predict rheumatoid arthritis (RA) disease activity, measured by the 28-joint count Disease Activity Score (DAS28). METHOD Veterans enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry with one year of data available for review before being assessed by the DAS28, were studied. Three models were d...

2012
Marloes Vermeer Hillechiena H Kuper Hein J Bernelot Moens Monique Hoekstra Marcel D Posthumus Piet LCM van Riel Mart AFJ van de Laar

INTRODUCTION Clinical trials have demonstrated that treatment-to-target (T2T) is effective in achieving remission in early rheumatoid arthritis (RA). However, the concept of T2T has not been fully implemented yet and the question is whether a T2T strategy is feasible in daily clinical practice. The objective of the study was to evaluate the adherence to a T2T strategy aiming at remission (Disea...

Journal: :Arthritis Research & Therapy 2005
Bert Vander Cruyssen Stijn Van Looy Bart Wyns Rene Westhovens Patrick Durez Filip Van den Bosch Eric M Veys Herman Mielants Luc De Clerck Anne Peretz Michel Malaise Leon Verbruggen Nathan Vastesaeger Anja Geldhof Luc Boullart Filip De Keyser

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3 mg/kg+methotrexate (MTX)) at weeks 0, 2, 6 and every 8 weeks thereafter. At week 22, 474 patients were still in follow-up, of whom 102 (21.5%), who were not optimally responding to treatment, received a dose i...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید